Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 août 2015 01h40 HE | Source: VALNEVA

VALNEVA Valneva Announces Two New EB66(R) Agreements

Valneva signs two new EB66® agreements with Italian firm Fatro (commercial license) and Japanese pharmaceutical company Kaketsuken (research license) The Company which has already...
22 juin 2015 12h32 HE | Source: VALNEVA

VALNEVA takes direct control over Marketing & Distribution of IXIARO(R) to increase margin and profitability

In support of the company's strategy to build a leading, independent and fully integrated vaccines biotech company, and to leverage synergies with its recently acquired second travel vaccine and...
26 mars 2015 02h56 HE | Source: VALNEVA

VALNEVA Announces Approval of an EB66(R)-based Prototype Influenza Vaccine in Japan

LYON, France, March 26, 2015 (GLOBE NEWSWIRE) -- The vaccine was developed by the Chemo-Sero Therapeutic Research Institute (Kaketsuken) in collaboration with GlaxoSmithKline using Valneva's...
17 mars 2015 02h58 HE | Source: VALNEVA

VALNEVA announces signing of an exclusive license agreement on EB66(r) Cell Line for Human and Veterinary Vaccines in China

LYON, France, March 17, 2015 (GLOBE NEWSWIRE) -- Valneva announces signing of an exclusive license agreement on EB66® Cell Line for Human and Veterinary Vaccines in People's Republic of...